Gene · 5682
PSMA1: proteasome 20S subunit alpha 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PSMA1: proteasome 20S subunit alpha 1. Genes, record 5682. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5682
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P25786 | Proteasome subunit alpha type-1 | 263 | 177 | Ensembl, GeneID, HGNC |
Source UniProt
Patents85
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 59499 | P25786 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 59500 | P25786 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 11387 | P25786 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 11387 | P25786 | Espacenet |
| US 11860162 B2 | 2024-01-02 | 1142 | P25786 | Espacenet |
| JP 2023106701 A | 2023-08-02 | 4 | P25786 | Espacenet |
| US 11694765 B2 | 2023-07-04 | 282 | P25786 | Espacenet |
| US 11474104 B2 | 2022-10-18 | 9 | P25786 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 67847 | P25786 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 170818 | P25786 | Espacenet |
1 to 10 of 85
See all 85 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BORTEZOMIB | CHEMBL325041 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| BORTEZOMIB D-MANNITOL | CHEMBL5315122 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| CARFILZOMIB | CHEMBL451887 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB | CHEMBL2141296 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB CITRATE | CHEMBL3545432 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| MARIZOMIB | CHEMBL371405 | 20S proteasome inhibitor | INHIBITOR | ChEMBL |
| OPROZOMIB | CHEMBL2103884 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
Trials1,241
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | CARFILZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07513129 | BORTEZOMIB | PHASE1 | ClinicalTrials.gov | |
| NCT07479979 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07464210 | BORTEZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07463807 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07428369 | BORTEZOMIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | BORTEZOMIB | PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | CARFILZOMIB | PHASE3 | ClinicalTrials.gov |
1 to 10 of 1,241
See all 1,241 trialsNIH grants754
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PSMA1 papers | Newest fiscal year |
|---|---|---|---|
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 7 | 2025 |
| ZIAAI000904 | Staphylococcal pathogenesis | 7 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| ZICES102445 | Gene Expression and Microarrays | 3 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 2 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 2 | 2025 |
| P30CA047904 | Cancer Center Support Grant | 2 | 2025 |
| P30CA225520 | Stephenson Cancer Center - Cancer Center Support Grant | 2 | 2025 |
1 to 10 of 754Source NIH's project files
See all 754 nih grantsPapers901
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PSMA1, PSMA5, and PSMB2 serve as prognostic biomarkers and are correlated with tumor-infiltrating leukocytes in HCC. | Epigenetics | 2026 | 42735232 | PubTator, text mining | PubMed |
| Commentary: Tumor associated neutrophils promote prostate cancer progression by mediating neutrophil trap secretion through PSMA1- NF-κB-HIF-1α signaling axis. | Front Immunol | 2026 | 42723983 | PubTator, text mining | PubMed |
| In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer. | ACS Nano Med | 2026 | 42639086 | PubTator, text mining | PubMed |
| CircUBE2I regulates YAP/TAZ signaling pathway through miR-659-3p/PSMA1 axis to promote human lung adenocarcinoma cell progression. | Exp Cell Res | 2026 | 42612899 | PubTator, text mining | PubMed |
| Integrated proteomics and machine learning for identifying candidate serum biomarkers in acute myocardial infarction-complicated cardiogenic shock: a prospective exploratory study. | Clin Proteomics | 2026 | 42477545 | PubTator, text mining | PubMed |
| Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation. | Int J Med Sci | 2026 | 41799753 | PubTator, text mining | PubMed |
| Systematic Identification of Molecular Signatures Dictating Therapeutic Effects of Clinically First-Line Chemotherapy Regimens for Human Gastric Cancer Patients Based on Organoid Model. | MedComm (2020) | 2026 | 41782964 | PubTator, text mining | PubMed |
| Multi-platform integration of brain and CSF proteomes reveals biomarker panels for Alzheimer's disease. | Brief Bioinform | 2026 | 41608987 | PubTator, text mining | PubMed |
| LDOC1 connects histone H2B monoubiquitination to tumor cell plasticity in non-small cell lung cancer. | Cell Commun Signal | 2026 | 41484780 | PubTator, text mining | PubMed |
| [Protein biomarker screening and functional analysis of salivary exosomes in patients with ulcerative colitis]. | Beijing Da Xue Xue Bao Yi Xue Ban | 2025 | 41131760 | PubTator, text mining | PubMed |
1 to 10 of 901
See all 901 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5682
GET https://conductscience.org/api/genes/v1/5682/patents?page=2